Dec 5, 2025
A highly accomplished and internationally recognised biopharma R&D executive with three decades of experience driving innovation from ideation through post-market approval. Known for strategic leadership at the senior executive level (Ferring, Janssen, Elan),...
Dec 5, 2025
Martin Heidecker, PhD, MBA, joined the AMR Action Fund in August 2021, bringing with him extensive international experience in venture capital, drug development, and pharmaceutical marketing. Most recently, he was Managing Director USA of Boehringer Ingelheim Venture...
Dec 5, 2025
Before joining Turenne Capital as Investment Director Healthcare in July 2022, Claire worked for 7 years in the Omnes Capital VC Healthcare team. She began her career in research at the Singapore Institute for Neurotechnology. Claire Poulard holds a master’s degree in...
Dec 5, 2025
Erick Lelouche is a graduate of the “Ecole Nationale Vétérinaire” in Nantes and of the “Institut d’Administration des Entreprises” in Montpellier. After practicing for a few years as a veterinarian, he joined Pfizer Animal Health where he held various positions in...
Dec 5, 2025
Marc, founding CEO of Antabio, is a molecular microbiologist with over 25 years’ experience in academia and biotech. Prior to founding Antabio, Marc held different research positions at various institutions globally such as CNRS and Inserm (France), CSIC (Spain) and...
